Zytoprotec Zytoprotec is developing drugs using a novel therapeutic approach – cytoprotection.
PD-protec® has shown safety and promising efficacy effects in a Phase I/II trial. A randomized, blinded, multicenter Phase II trial is planned to commence at the end of Q1 2014.
Worldwide, 2.3 million patients annually receive dialysis treatment. About 10 percent of these patients are treated with peritoneal dialysis (PD).
Cytoprotective PD solutions have the potential to significantly improve the outcomes of PD treatment and consequently to increase the share of PD within the overall dialysis market.